Influence of Colchicine Prescription in COVID-19-related Hospital Admissions: a Survival Analysis

Overview

Journal Ther Adv Musculoskelet Dis

Date 2021 Apr 15

PMID 33854571

Citations 6

Authors

Alfredo Madrid-Garcia

Ines Perez

Jose Ignacio Colomer

Leticia Leon-Mateos

Juan A Jover

Benjamin Fernandez-Gutierrez

Lydia Abasolo-Alcazar

Luis Rodriguez-Rodriguez

Affiliations

Soon will be listed here.

Abstract

Aims: To analyze the association between colchicine prescription and COVID-19-related hospital admissions in patients with rheumatic and musculoskeletal diseases (RMDs).

Methods: Patients attending a rheumatology outpatient clinic from a tertiary care center in Madrid, Spain, from 1 September 2019 to 29 February 2020 were included. Patients were assigned as exposed or unexposed based on whether they were prescribed with colchicine in their last visit to the clinic during the 6 months before the start of the observation period. Treatment changes during the observation period were also considered. The primary outcome was COVID-19-related hospital admissions between 1 March and 20 May 2020. Secondary outcome included COVID-19-related mortality. Several weighting techniques for data balancing, based and non-based on the propensity score, followed by Cox regressions were performed to estimate the association of colchicine prescription on both outcomes.

Discussion: The number of patients entered in the study was 9379, with 406 and 9002 exposed and unexposed follow-up periods, respectively. Generalized Boosted Models (GBMs) and Empirical Balancing Calibration Weighting (EBCW) methods showed the best balance for COVID-19-related hospital admissions. Colchicine prescription did not show a statistically significant association after covariable balancing (-value = 0.195 and 0.059 for GBM and EBCW, respectively). Regarding mortality, the low number of events prevented a success variable balancing and analysis.

Conclusion: Colchicine prescription does not play a significant protective or risk role in RMD patients regarding COVID-19-related hospital admissions. Our observations could support the maintenance of colchicine prescription in those patients already being treated, as it is not associated with a worse prognosis.

Plain Language Title: Colchicine influence in COVID-19-related hospital admissions.

Citing Articles

Colchicine and risk of hospitalization due to COVID-19: A population-based study.

Saenz-Aldea M, Salgado-Barreira A, Taracido Trunk M, Pineiro-Lamas M, Herdeiro M, Portela-Romero M J Med Virol. 2023; 95(2):e28496.

PMID: 36639903 PMC: 10107154. DOI: 10.1002/jmv.28496.

Determination of Colchicine in Pharmaceutical Formulations, Traditional Extracts, and Ultrasonication-Based Extracts of Pleniflorum (L.) Using Regular and Greener HPTLC Approaches: A Comparative Evaluation of Validation Parameters.

Alqarni M, Shakeel F, Aljarba T, Abdel-Kader M, Zaatout H, Alshehri S Plants (Basel). 2022; 11(13).

PMID: 35807719 PMC: 9268838. DOI: 10.3390/plants11131767.

Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation.

Tufan A, Matucci-Cerinic M Turk J Med Sci. 2021; 51(SI-1):3391-3404.

PMID: 34844296 PMC: 8771052. DOI: 10.3906/sag-2110-179.

The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet's syndrome.

Ozcifci G, Aydin T, Atli Z, Balkan I, Tabak F, Oztas M Rheumatol Int. 2021; 42(1):101-113.

PMID: 34825278 PMC: 8614218. DOI: 10.1007/s00296-021-05056-2.

Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine.

Vrachatis D, Papathanasiou K, Giotaki S, Raisakis K, Kossyvakis C, Kaoukis A J Clin Med. 2021; 10(21).

PMID: 34768648 PMC: 8584586. DOI: 10.3390/jcm10215128.

References

Sturmer T, Schneeweiss S, Avorn J, Glynn R . Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol. 2005; 162(3):279-89. PMC: 1444885. DOI: 10.1093/aje/kwi192. View

Schneeweiss S . Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006; 15(5):291-303. DOI: 10.1002/pds.1200. View

Brunetti L, Diawara O, Tsai A, Firestein B, Nahass R, Poiani G . Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19. J Clin Med. 2020; 9(9). PMC: 7565543. DOI: 10.3390/jcm9092961. View

Bourguiba R, Delplanque M, Vinit C, Ackermann F, Savey L, Grateau G . Clinical course of COVID-19 in a cohort of 342 familial Mediterranean fever patients with a long-term treatment by colchicine in a French endemic area. Ann Rheum Dis. 2020; 80(4):539-540. DOI: 10.1136/annrheumdis-2020-218707. View

Shaffer L . 15 drugs being tested to treat COVID-19 and how they would work. Nat Med. 2020; . DOI: 10.1038/d41591-020-00019-9. View

Xu X, Han M, Li T, Sun W, Wang D, Fu B . Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020; 117(20):10970-10975. PMC: 7245089. DOI: 10.1073/pnas.2005615117. View

Concato J, Peduzzi P, Holford T, Feinstein A . Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. J Clin Epidemiol. 1995; 48(12):1495-501. DOI: 10.1016/0895-4356(95)00510-2. View

Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G . Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 382(25):2411-2418. PMC: 7224609. DOI: 10.1056/NEJMoa2012410. View

Clerkin K, Fried J, Raikhelkar J, Sayer G, Griffin J, Masoumi A . COVID-19 and Cardiovascular Disease. Circulation. 2020; 141(20):1648-1655. DOI: 10.1161/CIRCULATIONAHA.120.046941. View

10.

Lopez-Otero D, Lopez-Pais J, Antunez-Muinos P, Cacho-Antonio C, Gonzalez-Ferrero T, Gonzalez-Juanatey J . [Association between myocardial injury and prognosis of COVID-19 hospitalized patients, with or without heart disease. CARDIOVID registry]. Rev Esp Cardiol. 2020; 74(1):105-108. PMC: 7494313. DOI: 10.1016/j.recesp.2020.08.003. View

11.

Scarsi M, Piantoni S, Colombo E, Airo P, Richini D, Miclini M . Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. Ann Rheum Dis. 2020; 79(10):1286-1289. PMC: 7509521. DOI: 10.1136/annrheumdis-2020-217712. View

12.

Zheng Y, Ma Y, Zhang J, Xie X . COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020; 17(5):259-260. PMC: 7095524. DOI: 10.1038/s41569-020-0360-5. View

13.

Varshney A, Wang D, Bhatt A, Blood A, Sharkawi M, Siddiqi H . Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis. Am Heart J. 2020; 232:105-115. PMC: 7586939. DOI: 10.1016/j.ahj.2020.10.065. View

14.

Fernandez-Gutierrez B . COVID-19 with Pulmonary Involvement. An Autoimmune Disease of Known Cause. Reumatol Clin (Engl Ed). 2020; 16(4):253-254. PMC: 7141447. DOI: 10.1016/j.reuma.2020.04.001. View

15.

Della-Torre E, Della-Torre F, Kusanovic M, Scotti R, Ramirez G, Dagna L . Treating COVID-19 with colchicine in community healthcare setting. Clin Immunol. 2020; 217:108490. PMC: 7261351. DOI: 10.1016/j.clim.2020.108490. View

16.

Terkeltaub R . Colchicine update: 2008. Semin Arthritis Rheum. 2008; 38(6):411-9. DOI: 10.1016/j.semarthrit.2008.08.006. View

17.

Lopez-Medina C, Ladehesa-Pineda L, Gomez-Garcia I, Puche-Larrubia M, Sequi-Sabater J, Armenteros-Ortiz P . Treatment adherence during the COVID-19 pandemic and the impact of confinement on disease activity and emotional status: A survey in 644 rheumatic patients. Joint Bone Spine. 2020; 88(2):105085. PMC: 7590637. DOI: 10.1016/j.jbspin.2020.105085. View

18.

Sandhu T, Tieng A, Chilimuri S, Franchin G . A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection. Can J Infect Dis Med Microbiol. 2020; 2020:8865954. PMC: 7588830. DOI: 10.1155/2020/8865954. View

19.

Montealegre-Gomez G, Garavito E, Gomez-Lopez A, Rojas-Villarraga A, Parra-Medina R . Colchicine: A potential therapeutic tool against COVID-19. Experience of 5 patients. Reumatol Clin. 2024; 17(7):371-375. PMC: 7229928. DOI: 10.1016/j.reuma.2020.05.001. View

20.

Mikuls T, Johnson S, Fraenkel L, Arasaratnam R, Baden L, Bermas B . American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2. Arthritis Rheumatol. 2020; 72(9):e1-e12. DOI: 10.1002/art.41437. View